Die richtige Ernährung bei Diabetes Typ 2 - Visite - NDR
By Abhishek Biswas, MD. Macrolide antibiotics carry a risk of qTc prolongation with resulting malignant arrhythmia such as torsades de points and sudden cardiac death.
Azithromycin carries the least risk of qTc prolongation among all macrolides, with the highest risk associated with erythromycin. Even then, the calculated risk of cardiovascular death associated with long term azithromycin prophylaxis in COPD patients Azithromycin bei Diabetes reported to be Azithromycin bei Diabetes in 20, Another side effect noted from azithromycin is hearing losswhich although being small in magnitude, is nonetheless important.
With that in mind, I present a synopsis of three new papers that shed some more light on the risk-benefit status of azithromycin:. It points out the fact that most studies have used different patient population as Azithromycin bei Diabetes subjects which in turn could be contributing to conflicting results.
For example, Ray and colleagues reported a high risk of cardiovascular mortality and sudden cardiac death in the first 5 days of starting therapy among those receiving azithromycin compared to those taking placebo or amoxicillin.
There were multiple criticisms that could limit the generalizability of this result. These included the observational nature of this study and the fact that the study was not designed to take into the account Azithromycin bei Diabetes impact of other cardiotoxic medications such as co-administration of antipsychotics.
On the other hand, Svanstrom et al studied the effects of azithromycin among young healthy adults. The risk was found to be similar to those patients taking penicillin V, however.
The study suggested that this increased cardiovascular risk was secondary to the disease process itself and not specific to the effects of azithromycin. These authors found that azithromycin, if used as a part of the treatment of pneumonia, reduced 90 day mortality. There was however, a significantly increased risk of nonfatal acute myocardial infarction reported with use of azithromycin. In spite of this result, the incidence of cardiac arrhythmias and heart failure was not Azithromycin bei Diabetes in the azithromycin arm.
These results seem contradictory since azithromycin reduced the risk of death but increased the incidence of cardiac events. The author surmises that it would be difficult to distinguish the contribution of the Azithromycin bei Diabetes disease to cardiac events. The NNT reported for azithromycin to prevent one death was 21 compared to the number needed Azithromycin bei Diabetes harm of for myocardial infarctions. Thus azithromycin treatment averted seven deaths for every myocardial infarction it Azithromycin bei Diabetes.
In the final studyHan et Azithromycin bei Diabetes attempted to find out the subgroups of patients with COPD who benefit from long term azithromycin therapy. A summary of their recently published results indicate that:. The authors accept that the study has some limitations because the study was not specifically powered for subgroup analysis.
However, the prevalence of cardiovascular Azithromycin bei Diabetes and risk factors among people with COPD makes "proper selection" of patients a challenge. Smoking cessation is the first line therapy for COPD, and active smokers might not derive benefit from azithromycin prophylaxis. Azithromycin Azithromycin bei Diabetes with sudden cardiac death.
Azithromycin prophylaxis: original article. FDA warns about sudden cardiac death from azithromycin. No spam. Share this: Click to share on Facebook Opens in new window Click to share on Twitter Opens in new window Click to email this to a friend Opens in new window. Sorry, your blog cannot share posts by email. PulmCCM Roundup 4.
Using bronchoalveolar lavage to evaluate ILD.